DigestRedComo funciona
Red
/
Empresas
Io
No verificado

Ionis Pharmaceuticals, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaIndustriaMedicina - VariosSalud

75 Comunicados de prensa

Ver todos los comunicados de prensa
29/07/2026
Mercado laboral
Ciencia
Biotecnología
Farmacéutica
Sanidad
Salud
Ionis announces Dr. Frank Bennett, chief scientific officer, to retire
Fuente
Ionis Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
29/07/2026
Web y redes sociales
Telefonía
Mercado de valores
Salud
Biotecnología
Farmacéutica
Cardiología
Ionis reports second quarter 2026 financial results and highlights progress on key programs
Fuente
Ionis Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
15/07/2026
Salud
Biotecnología
Farmacéutica
Cardiología
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Ionis to hold second quarter 2026 financial results webcast
Fuente
Ionis Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
14/07/2026
Eventos
Industria
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
Fuente
Ionis Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
13/07/2026
Farmacéutica
Salud
Medicina - Varios
Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome
Fuente
Ionis Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
09/07/2026
Industria
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Cardiología
Update on CARDIO-TTRansform Phase 3 trial of eplontersen in adults with transthyretin-mediated amyloid cardiomyopathy
Fuente
Ionis Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
06/07/2026
Farmacéutica
Biotecnología
Salud
Medicina - Varios
Industria
Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome
Fuente
Ionis Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
25/06/2026
Mercado laboral
Industria
Salud
Biotecnología
Farmacéutica
Cardiología
Ionis announces license agreement with Recordati for zilganersen in Alexander disease (AxD) in all countries outside the U.S.
Fuente
Ionis Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
24/06/2026
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
Fuente
Ionis Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
08/06/2026
Mercado laboral
Salud
Biotecnología
Farmacéutica
Cardiología
Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
Fuente
Ionis Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0